Personalizing age of cancer screening cessation based on comorbid conditions: model estimates of harms and benefits. Ann Intern Med. 2014;161(2):104-112.PubMedGoogle ScholarCrossref 19. Centers for Disease Control and Prevention (CDC). Vital signs: colorectal cancer screening test use: United ...
“In some cases, there is not a good alternative drug that has the same effectiveness,” said Dr. Lisa Holle, a clinical professor at the University of Connecticut School of Pharmacy. “So it can be extremely detrimental and potentially life-threatening.” Testicular ...
and National Cancer Institute medical centers, PIVOT will enroll over 1,000 individuals less than 75 years of age. The primary study end point is all-cause mortality. Secondary outcomes include prostate cancer- and treatment-specific morbidity and mortality, health status, predictors of disease-...
Materials and Methods Data Sources Population-based cancer incidence data in the United States are collected by the National Cancer Institute's (NCI's) Surveillance, Epidemiology, and End Results (SEER) program and the Centers for Disease Control and Prevention's National Program of Cancer Registries...
Design, Setting, and Participants This open-label, phase 3 randomized clinical trial (MYSTIC) was conducted at 203 cancer treatment centers in 17 countries. Patients with treatment-naive, metastatic non–small cell lung cancer who had no sensitizing EGFR or ALK genetic alterations were randomized to...
BACKGROUND: Achieving cancer early-detection goals remains a challenge, especially among low-income and minority populations. DESIGN/SETTING: A randomized trial based in 62 community health centers for the underserved in New York, New Jersey, and western Connecticut. Family physicians were on staff ...
5, 6, 7, 8, 9, 10, 11, 12, 13 The project was organized and funded by the IASLC and collected and analyzed more than 100,000 cases contributed by colleagues at 46 centers in more than 19 countries around the world. Data entry and analysis were performed by Cancer Research and ...
The SEER 22 registries’ data include 15 states (California [4 cancer registries], Connecticut, Georgia [3 cancer registries], Hawaii, Idaho, Illinois, Iowa, Kentucky, Louisiana, Massachusetts, New Jersey, New Mexico, New York, Utah, and Texas), Alaska Natives, and Seattle area in the state...
A review of advocate-scientist collaboration in federally funded environmental breast cancer research centers In the Long Island Breast Cancer Study Project (LIBCSP), a large population-based case-control study, blood levels of PAH-DNA adducts were associated with a modest 29-35% elevation in breas...
Refining the optimal chemotherapy regimen for good-risk metastatic nonseminomatous germ-cell tumors: a randomized trial of the Genito-Urinary Group of the French Federation of Cancer Centers (GETUG T93BP). Ann Oncol. 2007;18(5):917-92417351252PubMedGoogle ScholarCrossref 28. Clemm C, Boke...